Trials / Completed
CompletedNCT06946524
A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to Prefilled Syringe
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Subcutaneous Injection |
Timeline
- Start date
- 2025-05-08
- Primary completion
- 2025-11-25
- Completion
- 2025-11-25
- First posted
- 2025-04-27
- Last updated
- 2025-12-26
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06946524. Inclusion in this directory is not an endorsement.